BIOVECTRA and Revolution Biomanufacturing announced a partnership to integrate Revolution’s sequence‑optimization platforms (UTR and codon usage engineering) with BIOVECTRA’s GMP process development and manufacturing to deliver a single supplier pathway from mRNA design through sterile drug product. The alliance promises sponsors three‑ to fivefold expression gains from sequence engineering combined with clinical‑scale production, LNP formulation and sterile fill/finish. Both companies highlighted reduced risk and faster transfers for mRNA and pDNA programs. The deal reflects continued industry demand for modular developer‑to‑manufacturer solutions as mRNA therapeutics diversify beyond vaccines into tissue‑targeted and durable expression applications.